{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:03:18Z","timestamp":1784037798435,"version":"3.55.0"},"reference-count":25,"publisher":"FapUNIFESP (SciELO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sao Paulo Med. J."],"published-print":{"date-parts":[[2007,7]]},"abstract":"<jats:p>CONTEXT AND OBJECTIVE: Adverse drug reactions are a significant problem in patients on antiretroviral therapy (ART). We determined liver enzyme elevation frequencies in HIV-infected children and adolescents receiving ART, and their association with risk factors. DESIGN AND SETTING: Cross-sectional study, at the Pediatrics Immunodeficiency Division, University Hospital, Universidade Estadual de Campinas. METHODS: Medical records of 152 children and adolescents (54.6% male; median age 7.48 years) were analyzed, with a mean of 2.6 liver enzyme determinations per patient. Clinically, patients were classified in categories N (6), A (29), B (78) and C (39). Serum levels of aspartate aminotransferase and alanine aminotransferase were evaluated. Hepatotoxicity was scored as grade 1 (1.1-4.9 times upper limit of normality, ULN), grade 2 (5.0-9.9 times ULN), grade 3 (10.0-15.0 times ULN) and grade 4 (&gt; 15.0 times ULN). To assess hepatotoxicity risk factors, odds ratios (OR) and adjusted odds ratios (aOR) for age, gender, TCD4+ cell count, viral load and medication usage were calculated. RESULTS: We observed grade 1 hepatotoxicity in 19.7 % (30\/152) patients. No cases of grade 2, 3 or 4 were detected. There was a significant association between hepatotoxicity and use of sulfonamides (OR, 3.61; 95% confidence interval (CI), 1.50-8.70; aOR, 3.58; 95% CI, 1.44-8.85) and antituberculous agents (OR, 9.23; 95% CI, 1.60-53.08; aOR, 9.05; 95% CI, 1.48-55.25). No toxicity was associated with ART. CONCLUSIONS: One fifth of patients experienced mild hepatotoxicity, attributed to antituberculous agents and sulfonamides. Our results suggest that ART was well tolerated.<\/jats:p>","DOI":"10.1590\/s1516-31802007000400002","type":"journal-article","created":{"date-parts":[[2007,11,17]],"date-time":"2007-11-17T12:24:21Z","timestamp":1195302261000},"page":"205-209","source":"Crossref","is-referenced-by-count":14,"title":["Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy"],"prefix":"10.1590","volume":"125","author":[{"given":"Ana Cec\u00edlia Montes","family":"Gil","sequence":"first","affiliation":[{"name":"Universidade Estadual de Campinas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Lorenzetti","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gun Bergsten","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Moreno","family":"Morcillo","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adyl\u00e9ia Aparecida Dalbo Contrera","family":"Toro","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Tadeu Nolasco da","family":"Silva","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Marluce dos Santos","family":"Vilela","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"issue":"SS-2","key":"ref1","first-page":"1","article-title":"Surveillance for AIDS-defining opportunistic illnesses","volume":"48","author":"Jones JL","year":"1997","journal-title":"MMWR."},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00126334-200108150-00002","article-title":"Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy","volume":"27","author":"Nunez M","year":"2001","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection","volume":"283","author":"Sulkowski MS","year":"2000","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"issue":"6B","key":"ref4","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.1016\/S0002-9343(99)00390-3","article-title":"Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection","volume":"107","author":"Dieterich DT","year":"1999","journal-title":"Am J Med."},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/00002030-199810000-00025","article-title":"Hepatotoxicity after introduction of highly active antiretroviral therapy","volume":"12","author":"Rodriguez-Rosado R","year":"1998","journal-title":"AIDS","ISSN":"https:\/\/id.crossref.org\/issn\/0269-9370","issn-type":"print"},{"issue":"1","key":"ref6","first-page":"36","article-title":"Hepatotoxicity of antiretroviral therapy","volume":"5","author":"Kontorinis N","year":"2003","journal-title":"AIDS Rev."},{"issue":"4","key":"ref7","first-page":"96","article-title":"Antiretroviral therapy-related hepatotoxicity: predictors and clinical management","author":"Dore G","year":"2003","journal-title":"J HIV Ther."},{"key":"ref8","series-title":"Guidelines for measuring national HIV prevalence in population-based surveys"},{"key":"ref9","series-title":"Boletim Epidemiol\u00f3gico: Aids e DST","year":"2005"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00002030-200406003-00002","article-title":"Antiretroviral treatment in resource-poor settings: the Brazilian experience","volume":"18","author":"Teixeira PR","year":"2004","journal-title":"AIDS","ISSN":"https:\/\/id.crossref.org\/issn\/0269-9370","issn-type":"print"},{"key":"ref11","series-title":"Guia de tratamento cl\u00ednico da infec\u00e7\u00e3o pelo HIV em crian\u00e7as","year":"2004"},{"issue":"RR- 12","key":"ref12","first-page":"1","article-title":"1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age","volume":"43","author":"Caldwell MB","year":"1994","journal-title":"MMWR."},{"key":"ref13","series-title":"Table for grading severity of pediatric (< 3 months of age) adverse experiences"},{"key":"ref14","first-page":"555","article-title":"Age-dependent reference limits of several enzymes in plasma at different measuring temperatures","volume":"38","author":"Fischbach F","year":"1992","journal-title":"Klin Lab."},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0166-0934(91)90069-C","article-title":"NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection","volume":"35","author":"Kievits T","year":"1991","journal-title":"J Virol Methods","ISSN":"https:\/\/id.crossref.org\/issn\/0166-0934","issn-type":"print"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00002018-200528010-00004","article-title":"Hepatotoxicity of antiretrovirals: incidence, mechanisms and management","volume":"28","author":"Nunez M","year":"2005","journal-title":"Drug Saf."},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1001\/archpedi.156.6.568","article-title":"Efficacy and toxicity of antiretroviral therapy using 4 or more agents: application of a strategy for antiretroviral management in human immunodeficiency virus-infected children","volume":"156","author":"Melvin AJ","year":"2002","journal-title":"Arch Pediatr Adolesc Med."},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/tropej\/fmi086","article-title":"Adverse effects of antiretroviral therapy in HIV-1 infected children","volume":"52","author":"Shah I","year":"2005","journal-title":"J Trop Pediatr."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1086\/381499","article-title":"HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms","volume":"38","author":"Pol S","year":"2004","journal-title":"Clin Infect Dis."},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/01.inf.0000177281.93658.df","article-title":"Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age","volume":"24","author":"Chadwick EG","year":"2005","journal-title":"Pediatr Infect Dis J."},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.qai.0000134744.72079.cc","article-title":"Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001","volume":"38","author":"McConnell MS","year":"2005","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"11","key":"ref22","first-page":"1978","article-title":"Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients","volume":"90","author":"Ozick LA","year":"1995","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","article-title":"Antituberculosis druginduced hepatotoxicity: The role of hepatitis C virus and the human immunodeficiency virus","volume":"157","author":"Ungo JR","year":"1998","journal-title":"Am J Respir Crit Care Med."},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(01)00311-7","article-title":"Antiretroviral drug toxicity: a challenge for the hepatologist?","volume":"36","author":"Spengler U","year":"2002","journal-title":"J Hepatol."},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1378\/chest.99.2.465","article-title":"Toxic hepatitis with isoniazid and rifampin: A meta-analysis","volume":"99","author":"Steele MA","year":"1991","journal-title":"Chest","ISSN":"https:\/\/id.crossref.org\/issn\/0012-3692","issn-type":"print"}],"container-title":["Sao Paulo Medical Journal"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/spmj\/v125n4\/v125n4a02.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T17:22:16Z","timestamp":1495732936000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1516-31802007000400002&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S1516-31802007000400002"],"URL":"https:\/\/doi.org\/10.1590\/s1516-31802007000400002","relation":{},"ISSN":["1516-3180"],"issn-type":[{"value":"1516-3180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}